Cargando…
Multiple myeloma with t(11;14): impact of novel agents on outcome
Multiple myeloma (MM) patients with t(11;14) present unique biological features and their prognosis is not well established. We report a retrospective study of 591 MM patients, 17.3% of whom had t(11;14). It was designed to determine the prognostic impact of this abnormality and the effect of novel...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025259/ https://www.ncbi.nlm.nih.gov/pubmed/36935422 http://dx.doi.org/10.1038/s41408-023-00807-9 |
_version_ | 1784909288730263552 |
---|---|
author | Puertas, Borja González-Calle, Verónica Sobejano-Fuertes, Eduardo Escalante, Fernando Rey-Bua, Beatriz Padilla, Irene García-Sanz, Ramón Puig, Noemi Gutiérrez, Norma C. Mateos, María-Victoria |
author_facet | Puertas, Borja González-Calle, Verónica Sobejano-Fuertes, Eduardo Escalante, Fernando Rey-Bua, Beatriz Padilla, Irene García-Sanz, Ramón Puig, Noemi Gutiérrez, Norma C. Mateos, María-Victoria |
author_sort | Puertas, Borja |
collection | PubMed |
description | Multiple myeloma (MM) patients with t(11;14) present unique biological features and their prognosis is not well established. We report a retrospective study of 591 MM patients, 17.3% of whom had t(11;14). It was designed to determine the prognostic impact of this abnormality and the effect of novel agents on the response and outcomes. Three groups were established based on their cytogenetics: (1) t(11;14); (2) high-risk chromosomal abnormalities; and (3) standard risk (SR). After 80.1 months (1.2–273.8 months) of follow-up, no differences were observed in overall survival (OS) between the t(11;14) and SR groups (75.8 vs. 87.2 months; P = 0.438). Treatment of MM t(11;14) with novel agents did not improve their overall response rate (ORR) or complete response (CR) compared with those who received conventional therapy (ORR: 87.2 vs. 79.5%, P = 0.336; CR: 23.4 vs. 12.8%, P = 0.215). This effect translated into a similar PFS (39.6 vs. 30.0 months; P = 0.450) and OS (107.6 vs. 75.7 months; P = 0.175). In summary, MM t(11;14) patients did not benefit from the introduction of novel agents as much as SR patients did, indicating that other therapies are needed to improve their outcomes. |
format | Online Article Text |
id | pubmed-10025259 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-100252592023-03-21 Multiple myeloma with t(11;14): impact of novel agents on outcome Puertas, Borja González-Calle, Verónica Sobejano-Fuertes, Eduardo Escalante, Fernando Rey-Bua, Beatriz Padilla, Irene García-Sanz, Ramón Puig, Noemi Gutiérrez, Norma C. Mateos, María-Victoria Blood Cancer J Article Multiple myeloma (MM) patients with t(11;14) present unique biological features and their prognosis is not well established. We report a retrospective study of 591 MM patients, 17.3% of whom had t(11;14). It was designed to determine the prognostic impact of this abnormality and the effect of novel agents on the response and outcomes. Three groups were established based on their cytogenetics: (1) t(11;14); (2) high-risk chromosomal abnormalities; and (3) standard risk (SR). After 80.1 months (1.2–273.8 months) of follow-up, no differences were observed in overall survival (OS) between the t(11;14) and SR groups (75.8 vs. 87.2 months; P = 0.438). Treatment of MM t(11;14) with novel agents did not improve their overall response rate (ORR) or complete response (CR) compared with those who received conventional therapy (ORR: 87.2 vs. 79.5%, P = 0.336; CR: 23.4 vs. 12.8%, P = 0.215). This effect translated into a similar PFS (39.6 vs. 30.0 months; P = 0.450) and OS (107.6 vs. 75.7 months; P = 0.175). In summary, MM t(11;14) patients did not benefit from the introduction of novel agents as much as SR patients did, indicating that other therapies are needed to improve their outcomes. Nature Publishing Group UK 2023-03-20 /pmc/articles/PMC10025259/ /pubmed/36935422 http://dx.doi.org/10.1038/s41408-023-00807-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Puertas, Borja González-Calle, Verónica Sobejano-Fuertes, Eduardo Escalante, Fernando Rey-Bua, Beatriz Padilla, Irene García-Sanz, Ramón Puig, Noemi Gutiérrez, Norma C. Mateos, María-Victoria Multiple myeloma with t(11;14): impact of novel agents on outcome |
title | Multiple myeloma with t(11;14): impact of novel agents on outcome |
title_full | Multiple myeloma with t(11;14): impact of novel agents on outcome |
title_fullStr | Multiple myeloma with t(11;14): impact of novel agents on outcome |
title_full_unstemmed | Multiple myeloma with t(11;14): impact of novel agents on outcome |
title_short | Multiple myeloma with t(11;14): impact of novel agents on outcome |
title_sort | multiple myeloma with t(11;14): impact of novel agents on outcome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025259/ https://www.ncbi.nlm.nih.gov/pubmed/36935422 http://dx.doi.org/10.1038/s41408-023-00807-9 |
work_keys_str_mv | AT puertasborja multiplemyelomawitht1114impactofnovelagentsonoutcome AT gonzalezcalleveronica multiplemyelomawitht1114impactofnovelagentsonoutcome AT sobejanofuerteseduardo multiplemyelomawitht1114impactofnovelagentsonoutcome AT escalantefernando multiplemyelomawitht1114impactofnovelagentsonoutcome AT reybuabeatriz multiplemyelomawitht1114impactofnovelagentsonoutcome AT padillairene multiplemyelomawitht1114impactofnovelagentsonoutcome AT garciasanzramon multiplemyelomawitht1114impactofnovelagentsonoutcome AT puignoemi multiplemyelomawitht1114impactofnovelagentsonoutcome AT gutierreznormac multiplemyelomawitht1114impactofnovelagentsonoutcome AT mateosmariavictoria multiplemyelomawitht1114impactofnovelagentsonoutcome |